Attila Imre

1. IMRE, Attila, HREN, Rok, NAGY, Balázs. Early stage health economic evaluation of IMMUTOL gene therapy for relapsing/remitting multiple sclerosis in the Netherlands. In: ISPOR Europe 2025 : Powering Value and Access Through Patient-Centered Collaboration : 9-12 November 2025. Amsterdam: Elsevier, 2025. Str. s173. Value in Health, vol. 28, iss. 12, suppl. 1. ISSN 1524-4733. https://www.sciencedirect.com/science/article/pii/S1098301525032899, DOI: 10.1016/j.jval.2025.09.732. [COBISS.SI-ID 268158467]

2. IMRE, Attila, NAGY, Balázs, HREN, Rok. Early-stage health technology assessment of a curative genetherapy for multiple sclerosis. BJCP. British journal of clinical pharmacology. [Online ed.]. 2025, 9 str., ilustr. ISSN 1365-2125. DOI: 10.1002/bcp.70204. [COBISS.SI-ID 246676995]

3. FASSEEH, Ahmad Nader, ASHMAWY, Rasha, HREN, Rok, ELFASS, Kareem, IMRE, Attila, NÉMETH, Bertalan, NAGY, Dávid, NAGY, Balázs, VOKÓ, Zoltán. Generating realistic synthetic patient cohorts: enforcing statistical distributions, correlations, and logical constraints. Algorithms. Aug. 2025, vol. 18, iss. 8, art. no. 475, 29 str., ilustr. ISSN 1999-4893. Repository of the University of Ljubljana – RUL , DOI: 10.3390/a18080475. [COBISS.SI-ID 244713731]

4. IMRE, Attila, NAGY, Balázs, HREN, Rok. Assessing the early economic feasibility of a curative gene therapy for multiple sclerosis using a risk-adjusted valuation framework. Healthcare. Mar. 2026, vol. 14, iss. 5, art. no. 674, 17 str., ilustr. ISSN 2227-9032. https://www.mdpi.com/2227-9032/14/5/674, DOI: 10.3390/healthcare14050674. [COBISS.SI-ID 270881283]